ArticleScientific reports2025
Low neutrophil-to-lymphocyte ratio identifies secondary polycythemia in patients with erythrocytosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The neutrophil-to-lymphocyte ratio (NLR), a simple marker of systemic inflammation, may assist in differentiating polycythemia vera (PV) from secondary polycythemia (SP), especially when access to JAK2 mutation testing is limited due to cost or delayed turnaround. We retrospectively analyzed 655 patients with erythrocytosis who underwent JAK2 mutation testing between 2007 and 2024 across three South Korean tertiary hospitals. PV and SP were diagnosed per 2016 WHO criteria. NLR was calculated from complete blood counts and compared to serum erythropoietin (EPO) using receiver operating characteristic (ROC) analysis. The mean NLR was significantly higher in PV than SP (6.92 vs. 2.24, p < 0.001). NLR outperformed EPO in distinguishing PV (AUC 0.919 vs. 0.835, p < 0.001), and the combination further improved diagnostic accuracy (AUC 0.955). Notably, 98.8% (159/161) of patients with NLR < 1.5 had SP, suggesting these patients may safely undergo delayed JAK2 testing while secondary causes are prioritized. NLR may serve as a cost-effective triage marker to identify patients at low risk for PV, potentially reducing unnecessary molecular testing and expediting appropriate diagnostic pathways in erythrocytosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.